Biotech Values

[DewDiligence]

US Patent Expirations of Big-Selling Biologics (revised)

The listed dates below are the latest of the dates from three sources:
i) USPTO list of Hatch-Waxman patent extensions (#msg-69355910);
ii) Genentech’s SEC filings (#msg-69827819); and iii) Reuters (#msg-60342122).
(The latter two sources give only the year rather than the exact date.)


Epogen 2013
Neulasta 2015
Fabrizyme 9/27/2015
Rituxan 2016
Humira 12/31/2016
Amevive 1/30/2017
Tysabri 4/27/2017
Xolair 2018 Myozyme 8/18/2018
Avastin 2019
Herceptin 2019
Remicade 2019
Orencia 10/19/2019
Vectibix 4/8/2020
Lucentis 6/30/2020
Soliris 3/16/2021
Enbrel 11/22/2028 (based on new patent in #msg-69263618)